CDAK Projected Dividend Yield

Codiak BioSciences Inc ( NASDAQ : CDAK )

Codiak BioSciences is a clinical-stage biopharmaceutical company focused on the development of exosome-based therapeutics. One of Co.'s clinical stage programs, exoSTING, is an exosome therapeutic candidate delivering its proprietary STING agonist while expressing high levels of Prostaglandin F2 receptor negative regulator (PTGFRN) on the exosome surface to facilitate specific uptake in tumor-resident antigen-presenting cells. Co.'s other clinical stage program, exoIL-12, displays IL-12 in an active form on the surface of the engineered exosome. Co.'s third clinical stage program, exoASO-STAT6, overexpresses PTGFRN to selectively target uptake in M2-polarized tumor-associated-macrophages.

20 YEAR PERFORMANCE RESULTS